Skip directly to content

Referencias

  1. Laslett LJ, Alagona P Jr, Clark BA III, et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues. A report from the American College of Cardiology. J Am Coll Cardiol. 2012;60(25 suppl):S1-S49. http://gm.stijlfabriek.com/issues/issue-10/cardiovascular- diseases-in-poor-resource-settings/. Accessed September 7, 2014.
  2. Lakatta EG. Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons. Heart Fail Rev. 2002;7(1):29-49.
  3. Priebe HJ. The aged cardiovascular risk patient. Br J Anaesth. 2000;85(5):763-778.
  4. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics−−2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-e292.
  5. National Heart, Lung, and Blood Institute. Lower heart disease risk. What are the risk factors for heart disease? http://www.nhlbi.nih.gov/health/educational/hearttruth/lower-risk/risk-f.... Updated July 10, 2014. Accessed September 26, 2014.
  6. Maurer M. Age: a nonmodifiable risk factor? J Am Coll Cardiol. 2003;42(8):1427-1428.
  7. Kaplan NM. The diastolic J curve: alive and threatening. Hypertension. 2011;58(5):751-753.
  8. Mounier-Véhier C, Jaboureck O, Emeriau JP, Bernaud C, Clerson P, Carre A. Randomized, comparative, double-blind study of amlodipine vs. nicardipine as a treatment of isolated systolic hypertension in the elderly. Fundam Clin Pharmacol. 2002;16(6):537-544.
  9. Sniderman AD, Furberg CD. Age as a modifiable risk factor for cardiovascular disease. Lancet. 2008;371(9623):1547-1549.
  10. Zimlichman R. Treatment of hypertension and metabolic syndrome: lowering blood pressure is not enough for organ protection, new approach-arterial destiffening. Curr Hypertens Rep. 2014;16(10):479.
  11. Agabiti-Rosei E, Mancia G, O'Rourke MF, Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007;50(1):154-160.
  12. O’Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol. 2007;50(1):1-13.
  13. World Health Organization. Media centre. Cardiovascular diseases (CVDs) Fact sheet N°317. Updated March 2013. http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed August 29, 2014.
  14. Mendis S, Puska P, Norrving B, eds. Global Atlas on Cardiovascular Disease Prevention and Control. Geneva, Switzerland: World Health Organization; 2011.
  15. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014;129(25 suppl2):S1-S45.
  16. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, et al; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769-1818.
  17. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-2219.
  18. NICE Guidelines 2011. Hypertension in adults: diagnosis and management. August 2011; 1-38.
  19. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ.2009;338.
  20. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
  21. James PA, Oparil S, Carter BL. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520.
  22. Wright JT Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison Himmelfarb CR. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014;160(7):499-503.
  23. Levine CB, Fahrbach KR, Frame D, et al. Effect of amlodipine on systolic blood pressure. Clin Ther. 2003;25(1):35-57.
  24. Beckett NS, Peters R, Fletcher AE, et al; HYVET Study Group Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-1898.